PARP1 and female reproductive organ cancer: (“ovarian cancer” OR “endometrial cancer” OR “cervical cancer” OR “gynecologic cancer”) AND (“PD-1” OR “PD-L1” OR “immune checkpoint inhibitor” OR pembrolizumab OR nivolumab OR durvalumab OR dostarlimab) AND (“PARP inhibitor” OR olaparib OR niraparib OR rucaparib OR talazoparib OR veliparib)